We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Abbott Demonstrates End to End Laboratory Solutions

By LabMedica International staff writers
Posted on 31 Jul 2024

Abbott (Abbott Park, IL, USA) is returning to the ADLM Clinical Lab Expo (formerly AACC) in 2024 with new product launches, workshops, and live demonstrations at the show. More...

Abbott’s next-generation Alinity systems are taking center stage at ADLM 2024. The Alinity family is harmonized across key laboratory disciplines, streamlining critical interactions between individuals, systems, and information, and enabling labs to redefine performance. Abbott is demonstrating the Alinity ci-series of integrated clinical chemistry & immunoassay systems offering powerful integration across clinical chemistry and immunoassay. These systems can easily scale, combining up to four modules in multiple configurations to meet any laboratory's needs and maximize its operational efficiency. The Alinity c compact clinical chemistry system maximizes testing throughput with high-quality assays to deliver efficient and accurate performance. The Alinity I compact immunoassay system utilizes proven CHEMIFLEX chemiluminescent detection technology to provide greater confidence in results.

Abbott is also highlighting the Alinity h-series integrated hematology systems which deliver simplified workflows through an innovative design to streamline the hematology laboratory. The Alinity hq compact hematology system enables laboratories to run at maximum efficiency while the Alinity hs compact slidemaker stainer system for an automated workflow delivers consistency. Visitors to Abbott’s booth at ADLM 2024 can also experience the Alinity m fully integrated, automated, high-throughput molecular diagnostics analyzer with high-quality assays that delivers the next level of flexibility and efficiency to molecular labs. Also featuring at the show is Abbott’s award-winning i-STAT Alinity point-of-care system designed to be easy, accurate and connected, providing results in minutes and integrating diagnostic patient-testing directly into the clinical-care pathway.

Additionally, a Scientific Industry Workshop from Abbott led by an expert will focus on analytical and clinical aspects across high and low hs-cardiac troponin results, while covering factors that may lead to potential misdiagnosis of myocardial infarction. Abbott’s MED Talks and LAB Voice sessions will be 20-30 minute presentations covering a wide range of key topics impacting labs, physicians, and the healthcare space today. The presentations will offer attendees emerging details on research, findings, and outcomes.

Related Links:
Abbott


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Enterovirus Test
Quanty Enterovirus System
New
Droplet Digital PCR System
QX600 AutoDG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.